← Back to Search

CXL with MMC for Keratoconus

Phase 2
Waitlist Available
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month, 3 months, 6 months, 12 months and 18 months post-operation.
Awards & highlights

Study Summary

This trial is testing whether using a low concentration of MMC for a shorter duration can reduce corneal haze and scarring after CXL.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month, 3 months, 6 months, 12 months and 18 months post-operation.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month, 3 months, 6 months, 12 months and 18 months post-operation. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Corneal haze/scarring
Secondary outcome measures
Clinical haze grade
Glare
Higher-order aberrations

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: CXL with MMCActive Control1 Intervention
Patients who have undergone corneal cross-linking (CXL) with the application of Mitomycin C (MMC).
Group II: CXL without MMCPlacebo Group1 Intervention
Patients who have undergone corneal cross-linking (CXL) without the application of Mitomycin C (MMC).

Find a Location

Who is running the clinical trial?

Ciusss de L'Est de l'Île de MontréalLead Sponsor
71 Previous Clinical Trials
5,557 Total Patients Enrolled
~1 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top